Allianz SE

ALIZY Q1 2026

Reported: 2026-05-15

Allianz’s shares edged up 1.8% post-earnings, reflecting a broadly steady quarter with solid growth and resilient profitability, though the market remained cautious amid no clear upside surprise.

Key takeaways

Operating profit rose nearly 7% year-on-year, led by double-digit growth in P&C segment and a 6% (15% FX-adjusted) increase in Asset Management.
P&C delivered an 11% operating profit increase with a combined ratio of 91%, driven by balanced price and volume growth and robust underwriting.
Life & Health showed resilience despite FX headwinds and prior period disposals; underlying new business volumes were slightly up and new business value broadly stable.
Core net income increased 7% with an 18% ROE and 9% EPS growth, excluding the EUR 1.1 billion Bajaj disposal gain, which is being neutralized over 2026.
The Solvency II ratio remained strong at 221%, demonstrating balanced capital management amid market volatility.

View recap

Allogene Therapeutics, Inc.

ALLO Q1 2026

Reported: 2026-05-15

Shares dropped 8.2% reflecting investor disappointment with cautious forward outlook and the absence of clear near-term commercial catalysts, despite encouraging early clinical signals.

Key takeaways

SemiCell’s interim ALPHA-3 data showed a 58.3% MRD clearance rate versus 16.7% in the observation arm, indicating early biological activity but based on only 24 patients.
No treatment-related hospitalizations or severe side effects were noted, supporting outpatient administration potential.
ALLO-329 program advanced dose escalation with initial signs of clinical activity and tolerability, though still early stage.
Management emphasized a deliberate, stepwise clinical development strategy without providing updated commercial guidance or timelines.
The cautious tone and lack of immediate revenue drivers likely contributed to the negative stock reaction.

View recap

Applied Materials, Inc.

AMAT Q2 2026

Reported: 2026-05-15

Applied Materials shares edged up modestly by 0.9% following its Q2 fiscal 2026 report, reflecting a broadly in-line performance with expectations. While revenue and margins were notable, the market judged the results as steady rather than exceeding forecasts given the cautious tone around supply chain constraints and incremental 2026 equipment order pacing.

Key takeaways

Recorded highest gross margin in over 25 years, supported by operational execution and supply chain improvements.
Semiconductor equipment business expected to grow more than 30% in calendar 2026 amid expanding AI infrastructure demand.
Continued strong leadership in leading-edge foundry logic, DRAM, and advanced packaging, which together will drive over 80% of wafer fab equipment spending growth this year.
Introduced two new products enhancing gate-all-around transistor processing, aiming to bolster precision and performance in AI chip manufacturing.
Longer-term visibility improved with largest customers providing rolling 8-quarter forecasts, though some near-term constraints from clean room space availability remain.

View recap

AmpliTech Group, Inc.

AMPG Q1 2026

Reported: 2026-05-15

AmpliTech's shares jumped 19% after reporting substantial revenue growth and a sharp gross margin expansion that outpaced expectations, with no adjustments to full-year guidance despite supply chain headwinds.

Key takeaways

Revenue increased 48.6% year-over-year to $5.35 million, reflecting strong demand across key product lines.
Gross margin improved notably to 48% from 33% a year ago, driven by operational leverage and commercialization advances.
Net loss narrowed by 17.3% to $1.52 million, signaling progress toward profitability.
Balance sheet strengthened with cash and marketable securities rising to $18.4 million and working capital improving to $25.4 million.
Company maintained full-year revenue guidance, acknowledging potential shifts in timing due to external supply chain and geopolitical factors but remains confident in long-term growth prospects.

View recap

Avino Silver & Gold Mines Ltd.

ASM Q1 2026

Reported: 2026-05-15

Avino’s shares declined 2.2% following the Q1 report, reflecting investor caution despite stable operational progress and promising resource updates. The market appears to be weighing the tempered outlook and incremental nature of growth over immediate margin or volume expansion.

Key takeaways

Q1 production totaled just over 568,000 ounces, driven by stable mill throughput exceeding expectations with 14,000+ tonnes processed.
The company announced its inaugural mineral reserve estimate of 127 million silver equivalent ounces, marking a key milestone toward diversification and growth.
La Preciosa development contributed significantly, with encouraging grade improvements and completion of the 2025 drill program confirming high-grade silver zones outside current resources.
Record quarterly revenue of $39.4 million and a strong cash position of $139 million support organic growth initiatives, but no explicit guidance upgrade was provided.
Despite operational advances and investor recognition, the cautious tone on near-term production and the absence of margin expansion contributed to muted investor response.

View recap

authID Inc. Common Stock

AUID Q1 2026

Reported: 2026-05-15

authID’s shares jumped 10.1% following an earnings release that highlighted significant technology advances and a strengthened enterprise pipeline, signaling investor confidence in the company’s strategic repositioning despite no detailed financial metrics disclosed.

Key takeaways

AuthID secured $4.2 million in bridge financing, providing runway to support long sales cycles with large enterprise customers.
Targeted operating expense reductions expected to yield $3.5 million in annualized savings starting Q2 2026, reflecting disciplined cost management.
Launched the industry’s first quantum resistant biometric authentication platform, addressing emerging cybersecurity threats with a dual-layer encryption approach.
Progressed regulatory compliance capabilities with support for biometrically secured digital IDs and verifiable credentials, enhancing onboarding efficiency to two clicks.
Pipeline engagement includes over a dozen major enterprises across multiple sectors, with an emphasis on converting structured evaluations into contracted revenue.

View recap

Birkenstock Holding plc

BIRK Q2 2026

Reported: 2026-05-15

Birkenstock’s shares fell sharply by 10.1% after earnings as investors reacted negatively to margin pressure and signs of a cautious outlook amid rising inflation, tariff uncertainty, and geopolitical disruptions despite solid revenue growth.

Key takeaways

Reported revenue grew 8% to EUR 618 million, or 14% in constant currency, driven by strong regional growth including 30% in APAC and 14% in Americas.
Adjusted EBITDA margin slipped below prior levels, pressured by tariffs, FX headwinds, and rising energy costs, challenging the narrative of margin resilience.
EMEA growth was notably impaired by an estimated EUR 6 million impact from Middle East conflicts, reducing growth by ~300 basis points in the region and ~100 basis points company-wide.
Management reiterated fiscal 2026 revenue growth guidance of 13-15%, but heightened inflation and tariff risks raise doubts about delivery.
Direct-to-consumer retail expanded 60% in constant currency, aided by new store openings, but ongoing investments in online capability signal pressure on profitability going forward.

View recap

BK Technologies Corporation

BKTI Q1 2026

Reported: 2026-05-15

Shares fell 3.8% as investors focused on a cautious outlook, specifically the significant hike in the effective tax rate that will materially weigh on EPS growth in 2026 despite solid revenue and margin gains.

Key takeaways

Revenue rose 11.8% year-over-year to $21.3 million, driven by broad-based demand across federal, state, and local agencies.
Gross margin expanded to 51.8% from 47%, reflecting favorable product mix with increased adoption of higher-margin BKR 9,000 radios.
Operating income held steady at $3.3 million with an operating margin of 15.4%, despite higher SG&A expenses linked to investments in product development and innovation.
Diluted GAAP EPS increased to $0.69 from $0.55, but the effective tax rate jumped to 26% from 16% in 2025, expected to reduce EPS by roughly $0.44 in 2026 versus prior year.
After-tax free cash flow surged 44% to $4.1 million, underpinning a record cash balance of $29 million, supporting continued investment while maintaining capital discipline.

View recap

Brookfield Corporation Class A Limited Voting Shares

BN Q1 2026

Reported: 2026-05-15

Brookfield’s shares edged up modestly by 1.0% following Q1 2026 results, reflecting investor caution despite stable distributable earnings and ongoing asset management momentum.

Key takeaways

Distributable earnings totaled $1.6 billion for the quarter, with $6 billion generated over the past twelve months.
Asset Management division showed solid earnings growth fueled by continued fundraising success among institutional clients.
Operating businesses delivered stable cash flows anchored by resilient fundamentals across sectors.
Wealth Solutions advanced its global scale, notably with the recent acquisition of Just Group, adding $40 billion in insurance assets.
Management emphasized a disciplined, long-term capital allocation approach, highlighting the business’s resilience amid macroeconomic volatility without offering significant new financial guidance.

View recap

BitGo Holdings, Inc.

BTGO Q1 2026

Reported: 2026-05-15

Shares fell 17.2% following the quarter as investors reacted negatively to a cautious outlook masked by lower reported revenue driven by mixed accounting of derivatives versus spot trading activity and margin pressure.

Key takeaways

Reported revenue declined sequentially due to a shift from gross-basis spot trading to net-basis derivatives trading, obscuring underlying platform economics.
Total assets on platform declined in dollar terms to $63 billion, impacted by lower digital asset prices despite 29% YoY growth on a price-normalized basis.
Staked assets fell in nominal terms to $11.8 billion but increased 21% YoY when normalized for price movements.
Client base expanded 42% YoY to 5,569 firms and users grew to 1.2 million despite broad market headwinds.
Management emphasized ongoing investment in platform integration and strategic partnerships, but cautious near-term financial visibility likely weighed on sentiment.

View recap

Crescent Capital BDC, Inc.

CCAP Q1 2026

Reported: 2026-05-15

Shares of Crescent Capital BDC (CCAP) declined 8.3% following the quarter as investors reacted to weaker earnings driven by increased nonaccruals, lower base rates, and a cautious near-term outlook marked by a dividend cut and portfolio NAV pressure.

Key takeaways

Net investment income (NII) fell to $0.38 per share from $0.45 last quarter, primarily due to $0.04 per share impact from new nonaccruals and $0.02 per share from lower base rates.
The company waived $0.04 per share in incentive fees this quarter to maintain full dividend coverage, resulting in a reported $0.42 per share NII.
Net asset value (NAV) declined to $18.27 per share from $19.10, driven 65% by broader market mark-to-market factors and 35% from credit-specific pressures.
The quarterly base dividend was cut from $0.42 to $0.34 per share, reflecting a more conservative payout aligned with current earnings, though supplemented by three $0.03 per share special dividends through 2026.
Leverage was slightly above target at 1.3x due to delayed realizations, with liquidity remaining strong at $206 million available capacity and a $100 million planned facility upsize to aid refinancing and flexibility.

View recap

CorMedix Inc.

CRMD Q1 2026

Reported: 2026-05-15

CorMedix shares gained 5.7% following Q1 results that beat expectations on net revenue and adjusted EBITDA, leading the company to raise full-year guidance across key metrics including DefenCath sales despite anticipated reimbursement variability in the second half of the year.

Key takeaways

Q1 net revenue reached $127.4 million, significantly above prior consensus.
Adjusted EBITDA totaled $70 million, prompting an increase in full year guidance to $115 million–$135 million from a prior $100 million–$125 million range.
Full-year net revenue guidance was raised to $325 million–$345 million, up from $300 million–$320 million, driven by strong early performance and sustained DefenCath demand.
DefenCath full-year guidance increased to $175 million–$195 million, reflecting robust utilization despite the expiration of initial TDAPA reimbursement and transition to post-TDAPA add-on pricing in H2 2026.
The company announced positive top-line clinical data for REZZAYO, supporting upcoming FDA sNDA submission and potential 2027 launch, with planned commercial infrastructure investments in the latter half of 2026.

View recap

Cisco Systems, Inc.

CSCO Q3 2026

Reported: 2026-05-15

Cisco shares rallied 16.4% following Q3 results driven by significant upside in product orders and AI infrastructure demand, with broad-based growth across networking and hyperscaler segments clearly outperforming expectations.

Key takeaways

Q3 revenue reached a record $15.8 billion, up 12% year-over-year, fueled by 17% growth in product revenue.
Total product orders surged 35% year-over-year; excluding hyperscalers, orders still rose 19%, indicating strong underlying demand.
AI infrastructure orders from hyperscalers hit $1.9 billion in Q3, with FY26 full-year expectations raised to ~$9 billion, 4.5x FY25.
Networking products grew over 50%, led by triple-digit service provider routing and continued double-digit gains in campus switching, wireless (40%+ growth), and enterprise data center switching.
Acacia optics business delivered its strongest quarter with over $1 billion in orders, positioning Cisco as a market leader in coherent pluggable optics.

View recap

Capital Southwest Corporation

CSWC Q4 2026

Reported: 2026-05-15

Capital Southwest’s shares rose modestly by 2.4% following Q4 fiscal 2026 results, reflecting investor acknowledgment of steady portfolio growth and manageable credit risk, though the market held back from a stronger rally amid muted guidance signals.

Key takeaways

Investment portfolio expanded by $300 million or 17% to $2.1 billion over fiscal 2026.
Investment income climbed 14% to $232 million, demonstrating ongoing revenue growth.
NAV per share remained essentially flat at $16.69, signaling stable portfolio valuation despite market volatility.
Credit quality improved with nonaccruals down to 1.1% from 1.7%, benefiting from active portfolio management.
Dividend increased slightly to $2.56 per share even as benchmark rates (SOFR) declined by approximately 60 basis points.

View recap

CuriosityStream Inc.

CURI Q1 2026

Reported: 2026-05-15

Shares fell 14.6% as investors reacted negatively to the clear deceleration in near-term revenue and cautious outlook after CuriosityStream’s deliberate shift toward pilot agreements and technology investments which weighed on Q1 revenue growth and margin expansion.

Key takeaways

Q1 revenue was $15.2 million, showing only slight year-over-year growth and a sequential decline, reflecting the expected impact of newly prioritized pilot and framework agreements with large partners.
Subscription revenue remained flat compared to the prior quarter, offering little momentum in the core segment.
Licensing revenue, described as “lumpy,” was deliberately deprioritized in Q1 pending validation and scale-up of broader, more complex deals.
Management highlighted investments in technology and the expansion of owned IP to strengthen medium- and long-term revenue potential, but these moves weighed on near-term financials.
The outlook relies on anticipated revenue and cash flow growth later in 2026, driven primarily by a ramp in AI licensing and broader partnerships, though immediate results disappointed given the cautious tone and lack of acceleration.

View recap

Dare Bioscience, Inc.

DARE Q1 2026

Reported: 2026-05-15

Dare Bioscience's stock edged up modestly by 0.7% following Q1 2026 results, reflecting a neutral market reaction to updates on its women's health product pipeline and commercial strategy without significant surprises in guidance or margins.

Key takeaways

Focus remains on commercialization through 503B compounding and advancing proprietary, FDA-regulated women's health products.
Positive clinician reception for DARE to PLAY at ACOG indicates strong interest from OB/GYNs and sexual health specialists, signaling potential demand growth.
The company continues to emphasize building a diversified pipeline exclusively targeting women’s health conditions, aiming for recurring revenue via FDA-approved products.
No explicit guidance changes or margin pressures were noted that would cause material stock movement; market reaction suggests results were broadly in line with expectations.
The dual-path approach balancing compounding and branded consumer products remains central to execution and capital allocation.

View recap

Dragonfly Energy Holdings Corp. Common Stock (NV)

DFLI Q1 2026

Reported: 2026-05-15

Shares fell 1.5% following Q1 results as investors weighed ongoing softness in the RV market and cautious outlook, despite progress in heavy-duty trucking. The modest decline signals lingering concerns about near-term growth given industry headwinds.

Key takeaways

Revenue and adjusted EBITDA came in above guidance, but the RV market remains soft with year-over-year declines in industry shipments and retail sales.
Healthy adoption trends continue within OEM partnerships, driven by broader integration and increased energy storage content.
Heavy-duty trucking business shows growing momentum, highlighted by a significant $3 million purchase order from Stevens Transport for nearly 500 trucks, signaling early traction in this segment.
Cost reduction initiatives are delivering results, expected to yield approximately $9 million in annualized adjusted EBITDA improvement through expense cuts and rental space consolidation.
Investment continues in technology and IP, including a new patent allowance in Japan and a $527,000 Nevada Tech Hub grant to support in-house cell prototyping.

View recap

DLocal Limited Class A Common Shares

DLO Q1 2026

Reported: 2026-05-15

dLocal’s shares rose 4.0% following the earnings release, reflecting investor approval of sustained TPV growth and strong market positioning, despite some early quarter caution around margin progression.

Key takeaways

Processed total payment volume (TPV) surpassed $47 billion on a trailing 12-month basis, marking nearly a decade of consistent compounding growth (~90% CAGR).
Expanded geographic footprint to more than 60 countries with 38 active licenses and 16 additional license applications pending.
Maintained broad vertical diversification, with all verticals growing year-over-year, including high-growth areas such as remittances and ride-hailing.
Strong local payment method adoption continues to drive conversion rates, including up to 20 percentage points uplift versus international card processing.
Deepened merchant relationships with key clients expanding usage across multiple countries and product lines, underpinning long-term, scalable growth.

View recap

Doximity, Inc.

DOCS Q4 2026

Reported: 2026-05-15

Doximity's stock plunged 23% following Q4 results as investors were spooked by cautious near-term AI revenue guidance and margin pressure linked to elevated AI-related investments, despite solid engagement growth.

Key takeaways

Q4 revenue grew 5% year-over-year to $145 million; full-year revenue advanced 13% to $645 million.
Adjusted EBITDA margins compressed to 45% in Q4 from 55% in the full year; management flagged increased R&D, compute, and marketing expenses tied to AI initiatives.
Free cash flow hit a record $107 million in Q4, contributing to a 19% year-over-year increase in annual free cash flow to $317 million.
AI engagement accelerated significantly with 800,000 unique quarterly active prescribers (+30% YoY), half of whom used AI tools, but monetization remains nascent with minimal AI revenue anticipated this fiscal year.
Management emphasized an AI investment year strategy, increasing spending to build long-term AI capabilities and product offerings, but market reaction reflects concern over near-term profitability and cautious AI revenue outlook.

View recap

DarioHealth Corp.

DRIO Q1 2026

Reported: 2026-05-15

Shares fell 3.4% as investors reacted negatively to signs of cautious outlook and slower-than-expected revenue ramp from signed accounts, despite ongoing channel expansion and AI-driven engagement improvements.

Key takeaways

Revenue showed sequential growth for the second consecutive quarter, supported by channel ecosystem expansion and contracts signed in 2025.
The company announced a major new channel partner to potentially add access to ~65 million covered lives and 3,500 employer relationships, raising total reach beyond 175 million covered lives.
Management emphasized the strategic shift towards care delivery to open new revenue streams via outcomes- and claims-based models, leveraging over 100 peer-reviewed clinical studies.
Proprietary AI engine DarioIQ is actively deployed, with behavioral engagement programs reportedly delivering up to 40% improvement in targeted interventions.
Despite these positives, investors likely tempered enthusiasm due to cautious commentary on the timing and scale of revenue contribution from new contracts and broader strategic execution risks.

View recap

Exchange Income Corporation

EIF.TO Q1 2026

Reported: 2026-05-15

Shares rose 7.5% as Exchange Income Corporation delivered revenue and adjusted EBITDA growth driven by strong Aerospace & Aviation performance, a robust debt issuance, and upwardly revised guidance near the top of its range.

Key takeaways

Revenue rose 30% to $867 million in Q1, despite a 5% negative currency translation impact.
Adjusted EBITDA increased 27% to $166 million, reflecting strong operational leverage.
The Aerospace & Aviation segment benefited from acquisitions (Canadian North, Mach2), improved passenger loads, and contract expansions including ISR services.
Issued $600 million of unsecured notes (above initial $400 million plan) at 4.324%, supported by investment-grade rating and strong demand amid geopolitical volatility.
Management raised guidance toward the upper end of the $825–$875 million revenue range, citing accelerating momentum and stable business fundamentals.

View recap

Enovix Corporation Common Stock

ENVX Q1 2026

Reported: 2026-05-15

Enovix shares fell 13.6% as investors reacted negatively to cautious commentary on commercialization timelines and margin pressures despite progress in customer engagements and manufacturing. The market clearly signaled disappointment with the pace of scale and the lack of clear near-term revenue acceleration.

Key takeaways

Q1 revenue was $7.6 million, driven by Korean military contractors, and grew 49% year-over-year but remains limited in scale.
Non-GAAP gross margin contracted to 26.3%, highlighting ongoing margin pressures in early production stages.
Commercial production commenced for the A1 battery in smart eyewear, with shipments ramping expected through H2, but smartphone qualification remains in early stages with updated testing protocols only recently aligned.
Manufacturing yields improved, with most zones nearing or exceeding 90%, though Zone 1 dicing, a throughput bottleneck, is still being optimized with a hybrid dicing solution under development.
The company emphasized active customer dialogues and a growing pipeline ($130 million) — primarily in drone and industrial markets — but scaled commercial launch timelines remain cautious with broader smartphone commercialization expected in 2027.

View recap

Evolution Petroleum Corporation

EPM Q3 2026

Reported: 2026-05-15

Shares fell 6.3% following earnings as investors reacted negatively to a combination of margin pressure and challenges in key assets driven by weather disruptions, regional pricing dislocations, and a one-time transportation adjustment, signaling concerns over near-term earnings quality despite management's assurances.

Key takeaways

Reported results were weighed down by several nonoperational, timing-related items including natural gas price dislocations at Jonah and Barnett and a $1.2 million prior period transportation adjustment at Delhi.
Weather-related production disruptions, notably January ice storms, contributed to downtime across multiple fields, impacting volumes and near-term cash flow.
Production was essentially flat year-over-year at 6,700 BOE per day, supported by new acquisitions that offset declines elsewhere, illustrating portfolio diversification but without growth.
The minerals and royalty assets remain in early stages and currently contribute minimally but show potential as operator activity in Louisiana’s Haynesville and Bossier shales ramps up.
Guidance for Q4 anticipates normalization of prior adjustments and improved contribution from TexMex workovers, but the cautious tone around near-term headwinds likely dampened investor sentiment.

View recap

Evolv Technologies Holdings Inc. Class A Common Stock

EVLV Q1 2026

Reported: 2026-05-15

Evolv Technology’s shares fell 17.7% after the company’s Q1 report disappointed investors with a cautious outlook and decelerating subscription growth that undercut confidence in its path to sustained profitability.

Key takeaways

Revenue grew 45% year-over-year to $46.3 million, boosted by new customers, unit deployments, and a one-time increase from direct subscription fulfillment.
Annual recurring revenue (ARR) rose 20% to $127.3 million, reflecting slower subscription scaling relative to total revenue growth.
Adjusted EBITDA margin improved modestly to 8.5%, up from 6.4% in the prior year, but margin expansion remains limited amid ongoing investments.
Remaining performance obligation increased 18% to $299 million, yet this failed to reassure investors amid cautious management commentary on future growth.
The company highlighted geopolitical security challenges as a backdrop but offered only restrained guidance ahead of its June Investor Day, leaving investors uncertain on near-term momentum.

View recap

Faraday Future Intelligent Electric Inc.

FFAI Q1 2026

Reported: 2026-05-15

Faraday Future’s stock fell 5.3% following Q1 2026 results as investors reacted negatively to cautious execution and a slow scaling trajectory, with vehicle robotics commercialization deferred pending strategic funding and modest near-term revenue from early-stage robotics sales.

Key takeaways

Q1 revenue was $512,000, up 62% year-over-year, but still modest relative to full-year 2025 ($536,000).
Robotics generated initial revenue with 68 units shipped by end of April, introducing a new high-margin, asset-light revenue stream.
Vehicle robotics business remains on hold until strategic investment and funding are secured, indicating slow near-term growth potential.
Ecosystem revenue (agent skills, platform services, licensing) accounted for 26% of total revenue, signaling early-stage diversification.
Management emphasized disciplined, low-risk approach over scaled production, reflecting cautious execution.

View recap

FI

Simplify Macro Strategy ETF

FIG Q1 2026

Reported: 2026-05-15

Figma shares surged 21% post-earnings on a clear acceleration in revenue growth, stronger net dollar retention, and an upbeat raised guidance that outpaced market expectations.

Key takeaways

Q1 2026 revenue rose 46% year-over-year to $333 million, accelerating from 40% growth in the prior quarter.
Net dollar retention rate improved to 139%, the highest in over two years, up 3 percentage points sequentially.
Non-GAAP operating margin was a solid 16%, alongside a strong free cash flow margin of 27%.
Early monetization of AI features via Figma Weave and AI credits contributed to both growth and customer adoption.
Raised full-year revenue and operating profit guidance reflects management confidence driven by robust customer expansion and deeper AI integration.

View recap

Franco-Nevada Corporation

FNV.TO Q1 2026

Reported: 2026-05-15

Franco-Nevada reported broadly in line first-quarter results with a modest 0.3% stock increase reflecting no clear market surprise from record revenue and income driven by higher commodity prices and recent acquisitions. Despite favorable commodity trends, the market appears cautious on sustainability into upcoming quarters.

Key takeaways

Revenue increased 77% year-over-year, supported by higher gold and silver prices and contributions from four new acquisitions.
Adjusted EBITDA rose 84%, and adjusted net income was up 123%, reflecting strong operating leverage.
Total gold equivalent ounces (GEOs) sold increased 8% to 136,353; precious metal GEOs grew 17% to 117,980.
Commodity prices were a key driver, with gold up 70%, silver and platinum up 165% and 128%, respectively, during the quarter.
Oil price gains from geopolitical conflict are expected to boost energy revenues in Q2, but these benefits were not fully reflected in Q1 results.

View recap

Fermi Inc. Common Stock

FRMI Q1 2026

Reported: 2026-05-15

Shares surged 22.8% post-earnings as investors rewarded the company's clear progress on governance restructuring and commercial momentum, signaling renewed confidence in its ability to execute multibillion-dollar contracts amid a constrained power supply environment.

Key takeaways

Leadership overhaul includes removal of former CEO for cause and expansion of the Board to strengthen governance and operational discipline.
Interim CFO appointed with a strong public company financial track record to support scaling of Project Matador.
Established new corporate headquarters in Dallas to enhance stakeholder relationships and talent access, while maintaining Amarillo site presence.
Commercial engagement revived with reinitiated tenant conversations and new prospects entering the data room, boosting confidence in accelerating binding tenant agreements.
Liquidity remains solid with multiple capital levers available; the Board dismisses any immediate sale, focusing on long-term value creation.

View recap

FitLife Brands, Inc.

FTLF Q1 2026

Reported: 2026-05-15

FitLife’s stock rallied 10.2% following a first quarter marked by revenue growth driven primarily by the Irwin acquisition and sequential improvement in monthly revenue, despite ongoing margin pressures and organic revenue declines in core segments.

Key takeaways

Total revenue grew 59% year-over-year to $25.3 million, led by the Irwin acquisition, with Legacy FitLife revenue declining 22% year-over-year.
Gross margin contracted to 37.6% from 43.1% a year ago, reflecting Irwin’s lower margins, although both legacy and acquired businesses showed sequential margin improvement.
Adjusted EBITDA declined 3% year-over-year to $3.3 million, mainly due to higher amortization and interest expense related to the acquisition.
Legacy FitLife contribution decreased 27% to $4.3 million, with both online and wholesale sales down, impacted by lost revenue from major wholesale customers.
Irwin reported a 13% organic revenue decline largely due to out-of-stock issues but showed promising growth in its Amazon channel, with subscriber counts on Amazon increasing more than tenfold during the quarter.

View recap

Forward Industries, Inc.

FWDI Q2 2026

Reported: 2026-05-15

Forward Industries' shares rose 9.3% following results that highlighted strong execution on capital allocation and strategic initiatives, particularly around growing engagement and revenue diversification within the Solana ecosystem.

Key takeaways

Executed a $40 million institutional debt raise on favorable terms to fund a strategic 7.4% share repurchase, reducing shares outstanding.
Achieved meaningful operating expense savings through disciplined cost management initiatives.
SOL per share growth remained robust, currently above a 44% annualized compounding rate on an in-the-money basis.
Deepened engagement with the Solana ecosystem via tokenized FWDI shares (6.9 million tokenized) and high utilization (91%) of on-chain loan collateral.
Continued to benefit from Solana’s accelerating momentum in stablecoins, payments, and real-world assets, supported by key infrastructure developments like the Firedancer client rollout.

View recap

Galiano Gold Inc.

GAU Q1 2026

Reported: 2026-05-15

Shares were largely unchanged, rising a modest 0.8% post-earnings as results met expectations without significant surprises. Production and financial metrics tracked consistently with guidance, while cost pressures from new royalties and inflation were noted but managed.

Key takeaways

Q1 gold production totaled approximately 34,500 ounces, aligning with the midpoint of the first half production forecast.
Full-year production guidance remains steady at 140,000 to 160,000 ounces.
Operating costs and all-in sustaining costs (AISC) are in line with previous guidance despite inflationary pressures, notably on diesel, and the implementation of a new 12% sliding scale royalty.
Cash balance stayed robust at $115 million with additional liquidity from a $75 million undrawn credit facility.
Exploration and mining contract extension activities continue, positioning the company for stable operational continuity and long-term resource growth.

View recap

two

GILT Q1 2026

Reported: 2026-05-15

Shares dropped 19.2% following earnings as investors reacted negatively to a cautious outlook and evident deceleration in commercial segment momentum, despite growth in defense orders and technology milestones.

Key takeaways

Total Q1 revenue was $110.5 million, reflecting 20% year-over-year growth.
Adjusted EBITDA nearly doubled year-over-year to $15.1 million, driven primarily by defense contract wins and operational leverage.
Defense segment secured multiple orders: $16 million from a European Ministry of Defense, $9 million in Israel, $7 million for EnduroStream amplifiers supporting U.S. defense, and $6 million for U.S. Army field services.
Commercial segment showed steady but less dynamic performance with approximately 750 Sidewinder ESA terminals delivered and initial certification for in-cabin Line-fit solutions expected in Q4 2026.
Management emphasized technology investments and demonstrations, but gave a cautious tone on near-term commercial growth and competitive pressure, likely contributing to investor disappointment.

View recap

Glass House Brands Inc.

GLASF Q1 2026

Reported: 2026-05-15

Shares rose 8.5% following the quarter as investors responded positively to the confirmation of the medical cannabis rescheduling to Schedule III and the clear path toward interstate commerce and export opportunities, which expanded the company’s addressable market. Despite adjusted EBITDA losses and margin pressure, the market focused on the strategic upside from regulatory progress and operational expansion.

Key takeaways

Revenue of $41 million and biomass production of 152,000 pounds aligned with guidance.
Average selling price remained stable at $171 per pound, while cost of production stayed elevated at $175 per pound.
Gross margin held at 25%, below expectations, contributing to an adjusted EBITDA loss of $4.2 million.
Progress made on Greenhouse 2 expansion, with two-thirds of the new facility nearing completion for second-half production contribution.
Regulatory advances including DEA license conversions and export application filings underpin potential for new interstate and international sales channels.

View recap

Globant S.A.

GLOB Q1 2026

Reported: 2026-05-15

Globant’s Q1 revenue beat expectations, leading to a 4.1% jump in the stock, as AI-native services notably drove upside and management raised the lower end of full-year guidance while narrowing the range.

Key takeaways

Q1 2026 revenue reached $607.1 million, exceeding the high end of guidance.
Full-year revenue outlook midpoint reaffirmed; lower end of guidance raised and range narrowed for greater confidence.
Q2 guidance anticipates sequential growth with the upper range implying year-over-year expansion.
AI Pods annual recurring revenue hit $32.8 million with pipeline of $352 million and higher gross margins than the company average.
Original share repurchase program completed; new $125 million buyback authorized, totaling nearly 15% of market cap between programs.

View recap

Genmab A/S

GMAB Q1 2026

Reported: 2026-05-15

Genmab reported a largely in-line first quarter with revenue growth driven by solid execution across its proprietary portfolio, particularly EPKINLY and Tivdak, while maintaining development timelines and guidance; the stock was unchanged following the release.

Key takeaways

Total revenue increased 25% year-over-year, reflecting continued portfolio momentum.
Proprietary product sales grew 43%, with EPKINLY up 52% to $137 million and Tivdak rising 18% to $39 million.
The removal of hospitalization recommendation for EPKINLY in third-line DLBCL is expected to support broader outpatient use.
Phase III RAINFOL-02 trial enrollment completed ahead of schedule, potentially accelerating data readout in platinum-resistant ovarian cancer.
2026 remains catalyst-rich with multiple Phase III trial readouts anticipated, supporting pipeline progression and potential new launches in 2027.

View recap

GrainCorp Limited

GNC.AX Q2 2026

Reported: 2026-05-15

GrainCorp's shares dropped 13.5% on the back of investor disappointment with margin compression driven by a global oversupply of grains and a cautious outlook on grower selling activity and input pricing pressures. Despite reiterating full-year earnings guidance, concerns around subdued market conditions and margin pressure weighed heavily.

Key takeaways

Reported underlying EBITDA was $136 million for the half, reflecting operational resilience but margin headwinds from oversupplied grain markets.
Bulk materials handled increased from 1.2 million to 1.5 million tonnes, while animal nutrition sales rose modestly to 390,000 tonnes.
Elevated input prices and geopolitical uncertainty in the Middle East compressed margins and reduced grower selling activity.
Management reaffirmed FY26 earnings guidance of $200–240 million, signaling caution amid ongoing adverse market dynamics.
Cost reduction and portfolio optimization programs continue, including the pending sale of the GrainsConnect Canada joint venture to improve returns.

View recap

Humacyte Inc. Common Stock

HUMA Q1 2026

Reported: 2026-05-15

Humacyte's shares rose 9.9% post-earnings, reflecting positive market reception to progress in commercial expansion of Symvess, international regulatory advancements, and significant cost reductions from restructuring initiatives.

Key takeaways

First quarter Symvess sales grew to $0.5 million, up from $0.1 million a year earlier, marking early commercial traction.
The company strengthened its commercial leadership by hiring seasoned executives aimed at accelerating U.S. market penetration.
International commercialization advanced with the submission and acceptance of a marketing authorization application in Israel and a $1.475 million purchase commitment from Saudi Arabia.
A 25% workforce reduction and deferred hiring are expected to generate approximately $14.3 million in net cost savings for 2026, partially offset by a one-time severance charge estimated at $0.8 million.
Ongoing clinical progress includes enrollment in the V012 Phase III dialysis access trial, with interim data expected imminently.

View recap

SeaStar Medical Holding Corporation Common Stock

ICU Q1 2026

Reported: 2026-05-15

SeaStar Medical’s stock dropped 13.2% after the quarter, driven primarily by cautious commentary on the pace of enrollment in the NEUTRALIZE-AKI pivotal trial and the still small commercial scale of QUELIMMUNE revenue, which constrains near-term growth visibility.

Key takeaways

QUELIMMUNE revenue increased 69% year-over-year to $495,000, supported by the addition of 7 new hospital customers in Q1.
The company maintains a target of 15 new hospital adoptions for the full year, reflecting modest but steady customer growth.
Enrollment for the adult AKI pivotal trial stands at 198 of 339 planned patients, with efforts underway to expand clinical sites to complete enrollment by end of 2026.
Management highlighted ongoing discussions with the FDA on modular PMA submission and potential rapid approval pathways, but no new regulatory milestones were announced this quarter.
Despite commercial and clinical progress, the relatively early-stage adoption and cautious outlook on trial enrollment tempo likely contributed to investor disappointment.

View recap

InPost S.A.

INPST.AS Q1 2026

Reported: 2026-05-15

InPost's Q1 results showed volume and revenue growth supported by international expansion, but a modest 0.2% stock reaction reflects market neutrality amid slight margin pressure and ongoing transformation costs in the U.K.

Key takeaways

Total parcel volume increased 32% year-over-year to nearly 360 million parcels, driven by strong international growth.
Group revenue grew 31% to PLN 3.9 billion, with 53% coming from outside Poland, reflecting successful geographic diversification.
Adjusted EBITDA declined 4% to PLN 902 million, weighed down by transformation expenses in the U.K. market.
Network expansion continued with nearly 95,000 out-of-home points and 15,000 new automated parcel machines added over the past 12 months.
U.K. operation showed volume growth of 220% following Yodel consolidation but remained loss-making at PLN 49 million, though March was profitable marking early signs of turnaround.

View recap

Innoviz Technologies Ltd.

INVZ Q1 2026

Reported: 2026-05-15

Innoviz's shares plunged 20.9% following Q1 results as investors reacted negatively to the delay in recognizing key NRE revenues and the cautious outlook on near-term growth, undermining confidence despite ongoing product and market development.

Key takeaways

Reported Q1 revenues of $7.1 million, reflecting a partial deferral of NRE milestones due to additional content requests.
Management reiterated full-year revenue guidance of $67–73 million, but the timing shift in revenue recognition weighed heavily on investor sentiment.
NRE revenues remain a significant portion (~70%) of total revenue, with a planned gradual shift toward higher-margin LiDAR unit sales expected over time.
Newly entered defense and homeland security markets show early traction with agreements including one with Kela and a large holding group, indicating potential future growth avenues.
Despite announcing product advancements and accelerating shipments, notably a record first quarter unit output and progress in automotive programs, near-term financial delivery disappoints.

View recap

Invivyd Inc. Common Stock

IVVD Q1 2026

Reported: 2026-05-15

Invivyd’s stock plunged 21.1% following its Q1 2026 earnings release, driven primarily by a cautious outlook amid slowing COVID vaccine revenues and concerns over margin pressures, despite ongoing monoclonal antibody revenue growth.

Key takeaways

Monoclonal antibody revenues continued to grow, offsetting declines in COVID vaccine utilization and associated revenue.
The company slowed recruitment in its DECLARATION pivotal study to align with seasonal COVID-19 waves, potentially signaling challenges in near-term growth visibility.
Management highlighted increased government affairs activity but did not provide concrete guidance upgrades, reflecting a measured tone on near-term prospects.
The neutralization confirmation against Omicron BA.3.2 was acknowledged but seen as less impactful given the variant’s limited clinical threat.
Early pipeline expansion was noted, but no immediate commercial catalysts were detailed, leaving investor focus on current performance and near-term outlook.

View recap

Jack in the Box Inc.

JACK Q2 2026

Reported: 2026-05-15

Shares of Jack in the Box fell sharply by 14.2% following the quarter, reflecting investor disappointment primarily driven by ongoing same-store sales declines and significant margin compression amid sustained commodity and labor cost pressures.

Key takeaways

Same-store sales declined 3.8% in Q2, with franchise locations down 3.9% and company-owned stores off 2.8%, primarily due to weaker transactions despite some offset from menu price increases.
Restaurant-level margins compressed to 16.4%, down from 19.6% last year, pressured by a 110 basis point increase in food and packaging costs and a 180 basis point rise in labor costs as a percentage of sales.
Commodity inflation remained elevated with beef costs expected to stay in double digits through Q3, partially offset by deflation in dairy and other categories anticipated in Q4.
Franchise-level margins declined from 40.0% to 37.9% of franchise revenues, impacted by lower sales, fewer restaurants, and decreased lease termination fees.
Management emphasized operational initiatives and refreshed marketing strategies but provided a cautious outlook given ongoing cost headwinds and decelerating sales trends.

View recap

KULR Technology Group, Inc.

KULR Q1 2026

Reported: 2026-05-15

KULR’s shares dropped 5.9% following earnings, reflecting investor disappointment with cautious outlook and ongoing margin pressure despite strong revenue growth and operational improvements.

Key takeaways

Total revenue nearly doubled year-over-year, reaching $4.8 million, driven by 84% growth in product sales to $2.1 million.
Gross margin improved to 29% from 8% a year ago, though product sales margin remained relatively low at 26%.
Operating losses narrowed by approximately 22% year-over-year, indicating progress but continued unprofitability.
Management highlighted ongoing scaling efforts with expanded manufacturing capacity and commitment to battery business capital allocation.
While customer traction in UAV, defense, and space markets is expanding, the stock reaction indicates skepticism around the pace of profitability and outlook details.

View recap

Leslie's, Inc.

LESL Q2 2026

Reported: 2026-05-15

Leslie's stock surged 131.8% following Q2 results that notably beat expectations, driven by strong revenue growth, expanding customer base, and margin improvements fueled by an effective Price Drop initiative and ongoing cost optimization.

Key takeaways

Revenue grew 4.3% year-over-year, with comparable sales up 6.6% and total customer count rising 8%.
Adjusted EBITDA increased 26% year-over-year, reflecting margin expansion alongside cost control efforts.
The Price Drop campaign launched in March led to double-digit transaction growth and a >350 basis point conversion rate improvement in retail stores.
Reactivated customers grew more than 25%, powered by targeted marketing using zero-party data and integrated in-store signage updates.
Field organization restructuring and revised store-level incentives aim to drive sales growth across service, commercial, trade, and retail channels.

View recap

LogicMark Inc. Common Stock

LGMK Q1 2026

Reported: 2026-05-15

LogicMark's shares climbed 9.1% following first-quarter results, reflecting investor approval of revenue growth, improving gross margin, and reduced operating expenses that together narrowed the operating loss, signaling progress in the transition to a connected care platform.

Key takeaways

Revenue grew year-over-year, supported by sustained demand from VA partners and B2B channels.
Gross margin expanded compared to Q1 of last year, indicating operational leverage.
Operating expenses declined, contributing to a narrower operating loss.
The company is advancing its shift from personal safety hardware to a connected care platform with AI-enabled sensors and IoT integration.
Upcoming product launches include a wearable watch with biometric features and a connected-home hub, targeting senior living markets.

View recap

AEye Inc. Class A Common Stock

LIDR Q1 2026

Reported: 2026-05-15

AEye's stock dropped 14.4% following earnings as investors were disappointed by cautious forward guidance and indications of deceleration despite quarter-over-quarter growth in key engagement metrics.

Key takeaways

Revenue-generating customer count increased from 15 to 21 since the last quarter, signaling pipeline expansion but revenue remains a lagging indicator.
Issued quotes and active engagements grew nearly 40% quarter-over-quarter, reflecting improving commercial activity.
Quarterly revenue was up almost 60% year-over-year, driven by software-defined architecture and long-range sensing technology.
Management emphasized the strength in their pipeline and manufacturing partnerships but acknowledged that revenue growth is expected to lag these leading indicators.
The cautious tone on outlook and dependency on pipeline development likely fueled investor concern, contributing to margin pressure and uncertainty around near-term monetization.

View recap

Laird Superfood, Inc.

LSF Q1 2026

Reported: 2026-05-15

Shares rose 5.3% following an acquisition-driven quarter that expanded Laird Superfood’s scale and product portfolio beyond expectations, supporting investor confidence in its growth and integration strategy.

Key takeaways

Completed acquisitions of Navitas Organics and Terrasoul Superfoods shortly after quarter end, significantly broadening product assortment and distribution channels.
Q1 company growth was 20% year-over-year, fueled by wholesale and Amazon platform sales, including partial quarter contribution from Navitas.
Integration efforts are underway with early synergy realization, focusing on supply chain, finance, and commercial operations.
Margin pressure noted from Q1 inventory costed at elevated commodity prices and tariffs, but management expects improvement moving forward as costs decline and tariffs are removed.
Aggressive adoption of AI across forecasting, planning, and execution aims to enhance operational efficiency without incremental headcount.

View recap

Lifeway Foods, Inc.

LWAY Q1 2026

Reported: 2026-05-15

LifeWay Foods’ stock declined 4.6% after earnings as investors appeared disappointed by decelerating volume growth momentum and a cautious outlook implied by lapping prior-year distribution gains, despite record net sales and margin expansion.

Key takeaways

Net sales reached a record $63 million, up 36.7% year-over-year, driven entirely by volume increases in core products like drinkable kefir and high-protein farmer cheese.
Gross profit margin expanded 360 basis points to 27.5%, benefiting from improved manufacturing efficiencies and favorable milk pricing.
Selling, general, and administrative expenses rose 16.8% to $10.9 million but leveraged 300 basis points on revenue, reflecting ongoing investments in marketing and brand building.
Net income increased 32% to $4.7 million, or $0.30 diluted EPS, showing solid flow-through from revenue growth.
Commentary highlighted that 2026’s growth faces tougher comparisons due to substantial 2025 distribution gains, suggesting a more challenging environment ahead.

View recap

Moving iMage Technologies Inc. Common Stock

MITQ Q3 2026

Reported: 2026-05-15

Moving iMage Technologies beat expectations as initial revenue from the new DCS Cinema Loudspeaker business helped offset a 4.9% decline in overall revenue, driving a 4.4% stock gain. Improved gross margins and expanding international reach contributed to cautious optimism despite seasonally slower project activity.

Key takeaways

Q3 revenue declined 4.9% year-over-year to $3.4 million, reflecting typical seasonal softness and slower customer project activity.
The newly acquired DCS Loudspeaker business generated $460,000 in revenue in its first full quarter, providing a strategic new growth avenue and expanded geographic footprint.
Gross profit rose 11% to $1.2 million, with gross margin expanding to 34.8% from 29.8%, indicating progress in cost structure and product mix improvements.
The company highlighted industry tailwinds in premium large format auditoriums, immersive audio, and ongoing xenon-to-laser projection upgrades as drivers for future demand.
Management emphasized a consultative, systems-integration approach aimed at long-term customer engagement rather than simple product sales, supporting cautious confidence in the outlook.

View recap

Milestone Scientific Inc.

MLSS Q1 2026

Reported: 2026-05-15

Shares dropped 4.3% as investors were disappointed by flat revenue and continued shipment delays in the Middle East, which weighed on growth despite cost-cutting efforts and early traction in medical revenue.

Key takeaways

Total revenue held steady at approximately $2.2 million year-over-year, impacted by $200,000 in delayed Middle East shipments due to regional conflict.
Gross margin slightly declined to 72.3% from 73.8%, indicating modest margin compression.
Operating loss improved by 58% to $828,000, driven by a 30% reduction in operating expenses (~$1.3 million savings).
Medical segment revenue more than doubled to around $108,000, reflecting early-stage adoption of CompuFlo but still a small contribution overall.
Management reaffirmed 2026 revenue guidance of $9.8 million to $10.2 million, projecting double-digit growth and reduced cash burn despite near-term headwinds.

View recap

Munchener Ruckversicherungs-Gesellschaft Aktiengesellschaft in Munchen

MUV2.DE Q1 2026

Reported: 2026-05-15

Munich Re's shares edged down 0.1% following Q1 results that showed solid underlying underwriting performance offset by weaker investment returns and cautious outlook on capital markets. Investors appeared unimpressed by the investment-related headwinds which dampened overall profitability despite strength in core reinsurance and primary insurance segments.

Key takeaways

Net result of EUR 1.7 billion in Q1 delivered solid operating performance but was weighed down by investment portfolio volatility and negative fair value changes in fixed income and equities.
Return on investments reported at 2.9%, below full-year guidance, reflecting market volatility and temporary accounting effects on inflation-linked bonds; reinvestment yield improved to 4.2%.
P&C reinsurance combined ratio stood at 66.8%, benefiting from benign major loss experience; normalized combined ratio at 80.3%, consistent with full-year guidance but with noted upward pressure from renewals and increased major loss expectations.
April renewals saw an 18.5% reduction in treaty volume to maintain portfolio quality amid competitive pricing, with a risk-adjusted portfolio decline of 3.1%.
ERGO contributed a net result of EUR 235 million with improved Life & Health technical performance and solid P&C results, although international Life & Health profitability was impacted by a one-off portfolio sale.

View recap

MicroVision, Inc.

MVIS Q1 2026

Reported: 2026-05-15

MicroVision's shares dropped 21.1% as investors reacted negatively to what appears to be cautious, early-stage commercial traction and integration progress, with no clear evidence of meaningful revenue acceleration or margin improvement to justify the stock prior to scaling.

Key takeaways

Q1 marked the start of commercial revenue but no specific figures or guidance upgrades were provided to signal acceleration.
Integration of Luminar and Scantinel assets completed operationally, though benefits remain largely aspirational with product portfolio breadth emphasized over near-term sales impact.
Shipments have restarted in industrial markets, and repeat orders continue, yet these appear modest and early in their ramp phases.
Management highlighted progress and confidence, but refrained from updating growth or margin outlook, underscoring ongoing execution risks.
Market reaction signals investor skepticism around the pace at which the combined technologies will translate into sustainable commercial and financial performance.

View recap

Nebius Group N.V.

NBIS Q1 2026

Reported: 2026-05-15

Nebius’s shares surged 23.5% following an upbeat report driven by strong execution across capacity expansion, platform development, and customer demand that clearly beat market expectations.

Key takeaways

Contracted power capacity rose to more than 3.5 gigawatts, surpassing prior guidance and with a new Pennsylvania site adding 1.2 gigawatts.
The company enhanced its full-stack AI platform with three strategic acquisitions—Tavily, Eigen, and Clarifai—to strengthen inference optimization and agentic search capabilities.
Demand momentum accelerated with pipeline generation growing 3.5x quarter-over-quarter, and broad customer adoption spanning fintech, robotics, life sciences, and traditional industries.
CapEx guidance increased to $20–25 billion for 2026 to support anticipated 2027 capacity and rising customer commitments, including a marquee $27 billion contract with Meta.
Nebius raised over $6 billion of capital in the quarter, boosting its cash position above $9 billion and paving the way for continued large-scale financing initiatives.

View recap

Nano Nuclear Energy Inc

NNE Q2 2026

Reported: 2026-05-15

Shares edged up modestly by 1.8% following Q2 results as investors took note of regulatory progress and commercial developments, though the market reaction signals no significant positive surprise or setback.

Key takeaways

Submitted a formal construction permit application (CPA) to the U.S. NRC for the KRONOS MMR full-scale prototype, marking an important regulatory milestone.
Completed a feasibility study for supplying up to 1 gigawatt of power to a major AI data center and manufacturing campus in Texas, progressing commercial pipeline.
Advancing M&A and strategic partnership discussions aimed at vertical integration across the nuclear fuel supply chain.
Highlighted continued support from evolving NRC licensing frameworks (Part 53 and Part 57), which could streamline deployment timelines.
No explicit margins, guidance revisions, or key metric slowdowns mentioned that would materially sway near-term investor sentiment.

View recap

Nu Holdings Ltd. Class A Ordinary Shares

NU Q1 2026

Reported: 2026-05-15

Nu Holdings shares declined 4.9% following the earnings release, likely reflecting investor disappointment with margin pressures and increasing provisions despite top-line growth, suggesting rising costs and credit expenses weighed on the outlook.

Key takeaways

Customer base expanded to over 135 million, including 115 million in Brazil and 15 million in Mexico, highlighting continued user growth.
ARPAC reached approximately $16 per active customer, marking sequential expansion and contributing to record revenue of $5 billion for the quarter.
Efficiency ratio declined below 18%, partly driven by structural improvements but also influenced by timing benefits; an indicator of margin pressure amid growth investments.
Provisions increased due to seasonality, growth, and portfolio mix, signaling higher credit costs without indicating asset quality deterioration.
Despite operational progress and a milestone IFRS profit in Mexico, higher provisions and pressure on margins appear to have dampened investor enthusiasm.

View recap

Ondas Holdings Inc.

ONDS Q1 2026

Reported: 2026-05-15

Ondas led with substantial revenue and backlog growth that significantly outpaced prior targets, driving a +26.5% stock reaction as the market rewarded its rapid scaling and early achievement of product-level profitability.

Key takeaways

Q1 2026 revenue reached $50.1 million, a tenfold increase year-over-year and over 25% above the high end of prior guidance.
Revenue growth was broad-based, led by counter-drone and defense-related products, notably the Centrix cyber over RF platform and Iron Drone interceptor systems.
Product-level EBITDA profitability was achieved approximately two quarters ahead of schedule, signaling operational progress.
Backlog surged past $450 million following acquisitions, providing strong visibility into 2026 and beyond.
The balance sheet remains robust with roughly $1.4 billion in cash and short-term investments, supporting continued strategic investments and growth initiatives.

View recap

Optex Systems Holdings, Inc

OPXS Q2 2026

Reported: 2026-05-15

Shares declined 4% as investors reacted negatively to the cautious outlook driven by delays in government funding and deceleration in revenue growth, despite margin improvements and a solid backlog.

Key takeaways

Q2 revenue plunged to $600K from $10.7M a year ago due to federal government shutdown and delayed contract approvals, with first-half revenue roughly flat at $18.8M vs. $18.9M last year.
Gross margin improved to 35.2% from 31.3% last year, aided by the completion of loss-making contracts and operational efficiencies.
Operating expenses rose sharply to $1.7M for the quarter (+$600K YoY) driven by leadership transitions, R&D investments, compliance, and inflationary pressures.
Adjusted EBITDA declined year-over-year to $2M from $2.4M in Q2, reflecting lower volumes and higher spending.
Orders and backlog showed modest growth, with backlog at $36.6M, supporting a cautious view that revenue will recover in H2 but remains pressured in the near term.

View recap

Orezone Gold Corporation

ORE.TO Q1 2026

Reported: 2026-05-15

Orezone’s share price rose 3.7% post-earnings, reflecting investor optimism around the successful completion of the Bomboré hard rock expansion and the transformative Casa Berardi acquisition, which together position the company for meaningful production growth.

Key takeaways

Bomboré mine achieved commercial production of its Stage 1 hard rock expansion in January, running 10% above nameplate capacity.
The strategic acquisition of Casa Berardi gold mine adds diversification and scale, with production from this asset beginning in Q2 2026.
Q1 production totaled 38,789 ounces of gold, mostly from Bomboré (37,563 oz), with Casa Berardi contributing 1,226 oz from only 5 days of operation post-acquisition.
Operating cash flow was a record $175.6 million, supported by a $100 million gold stream deposit from Franco-Nevada.
All-in sustaining costs were $2,245/oz, within guidance despite lower head grades caused by emulsion supply issues impacting access to higher-grade ore.

View recap

Planet 13 Holdings Inc.

PLNH Q1 2026

Reported: 2026-05-15

Shares fell 1.4% following Q1 results that reflected the drag from the California divestiture and the absence of a one-time loyalty benefit. Despite underlying revenue stability and margin resilience, investors remain cautious amid ongoing market headwinds and a cautious near-term outlook.

Key takeaways

Total revenue declined sequentially to $21.1 million from $25.2 million, primarily due to the exit from California ($2.5 million impact) and the non-recurrence of a Florida loyalty accrual benefit from Q4.
Underlying revenue, excluding these items, was approximately flat quarter-over-quarter with April trends tracking in line with internal Q2 plans.
Gross margin held steady at 44.6%, improving 5.4% sequentially on an adjusted basis after excluding the prior quarter’s loyalty benefit; margin pressure was partly from selling remaining California inventory below cost.
Adjusted EBITDA loss widened to $2.3 million from $0.3 million sequentially, driven mainly by the nonrecurrence of the Florida loyalty benefit and the California exit costs.
Cost discipline continues with G&A down $800,000 sequentially to $11.2 million and lowered nearly $3 million year-over-year, poised for further efficiencies in 2026.

View recap

Parex Resources Inc.

PXT.TO Q1 2026

Reported: 2026-05-15

Shares declined 3.4% post-earnings as investors were disappointed by the modest production growth and cautious near-term operational outlook despite strategic acquisitions. Market reaction reflects concerns about slower standalone production ramp-up and deferred scale benefits from the Frontera and Magdalena transactions.

Key takeaways

Q1 production averaged just under 45,000 BOE/day, below prior quarter averages, with expected exit rate around 45,000 BOE/day, signaling limited near-term growth.
Strategic acquisitions (Frontera for $725 million and Magdalena partnership) set stage to nearly double production long term but benefits are yet to materialize operationally.
Exploration progress includes six wells in Block 111 with four positive results; one well producing ~1,500 barrels/day; cost-effective drilling at ~$2 million per well vs typical $6 million.
Nonrecurring charges of $17 million impacted Q1 financials, including a temporary corporate wealth tax and site restoration costs.
Integration plans underway for new assets with anticipated synergies, but execution risk and timing remain key near-term uncertainties.

View recap

Reed's, Inc.

REED Q1 2026

Reported: 2026-05-15

The stock plunged 27.2% as investors reacted negatively to broad operational weaknesses, including disappointing guidance, sales execution problems, margin pressure, and a cautious outlook for the remainder of 2026.

Key takeaways

Inventory liquidation and write-offs from discontinued and aged SKUs weighed on Q1 results.
Elevated SG&A expenses were misaligned with current business scale, prompting immediate cost-cutting actions including headcount reductions.
Multiple sales execution challenges affected topline, notably the disruption from packaging changes, limited promotional support, and missed category reviews limiting shelf placement.
Gross margins compressed due to rising input and wholesale costs with pricing adjustments only starting late in the quarter.
Management highlighted ongoing efforts to rebuild retail and distributor relationships, expand coverage through a third-party sales agency, revamp e-commerce initiatives, and implement operational improvements, but results remain below expectations with substantial recovery work ahead.

View recap

Algorhythm Holdings Inc.

RIME Q1 2026

Reported: 2026-05-15

Algorhythm's stock rose 3.8% after the quarter, reflecting investor approval of significant revenue growth and customer expansion that outpaced concerns around debt restructuring and capital allocation decisions.

Key takeaways

Revenue grew over 70% sequentially quarter-over-quarter, marking a notable acceleration in top-line momentum.
The company expanded its customer base to 14 clients and increased its dedicated truck fleet by 30% since year-end.
Strategic additions included marquee customers like Coca-Cola India and MTR Foods, supplementing existing partnerships with major brands such as Procter & Gamble and Unilever in India.
Despite deferring a $1.5 million promissory note payment, management emphasized this as a deliberate capital allocation choice to prioritize growth investments over debt repayment.
The balance sheet showed improvement with a $9.5 million secured prepaid purchase financing closed in February and $10.9 million cash on hand at quarter end.

View recap

Snail, Inc. Class A Common Stock

SNAL Q1 2026

Reported: 2026-05-15

Snail, Inc. stock surged 115.1% following its Q1 2026 earnings, driven by sustained engagement and strong unit sales in the ARK franchise alongside clear visibility on three AAA titles entering final development phases, signaling confidence in future growth potential beyond its core IP.

Key takeaways

ARK franchise remained stable with ASE selling over 573,000 units; ASA total units sold increased to 1.4 million for the quarter, supported by the Steam Winter Event and ARK Lost Colony DLC launch.
ARK Mobile downloads reached approximately 11.9 million with average daily active users over 141,000.
Upcoming releases include ARK ASA expansions and a significant $11 million in deferred revenue recognition from the ARK Genesis Part 1 remake launch.
Three AAA titles—For the Stars, Nine Yin Sutra: Immortal, and Nine Yin Sutra: Wushu—are in late development stages, aiming to broaden revenue streams and diversify Snail’s exposure beyond ARK.
The dual strategy with Nine Yin Sutra titles leverages a historically strong IP with a large existing fan base in China, positioning Snail for market expansion in the Wuxia genre.

View recap

SoftBank Corp.

SOBKY Q4 2026

Reported: 2026-05-15

SoftBank's stock was largely unchanged, edging up 0.2% after reporting fiscal year 2025 results that featured moderate revenue and profit growth but were weighed down by a ransomware attack in the Media & EC segment. The market’s muted reaction reflects cautious sentiment despite record revenue and free cash flow achievements.

Key takeaways

Revenue grew 8% year-on-year to JPY 7,038.7 billion, reaching a record high and surpassing the JPY 7 trillion milestone a year earlier than expected.
Operating income increased 5% to JPY 1,042.6 billion, supported by double-digit growth in Enterprise and Distribution segments and more than doubling in Financial, though offset by a >JPY 30 billion impact from a ransomware attack at ASCO within Media & EC.
Net income rose 5% to a record high of JPY 550.8 billion; primary free cash flow also hit a record JPY 633.6 billion.
Dividend was maintained at JPY 8.6 per share, consistent with prior guidance, with a planned increase to JPY 8.8 starting FY 2026.
SoftBank outlined an ambitious new medium-term plan focusing on AI infrastructure and services, targeting 10% CAGR in operating income to JPY 1.7 trillion by FY 2030, though investors appear to be weighing near-term execution risks.

View recap

STAAR Surgical Company

STAA Q1 2026

Reported: 2026-05-15

STAAR Surgical’s shares rose 9.1% following first quarter results driven by solid revenue growth and a return to adjusted EBITDA profitability, with China’s market recovery and U.S. sales milestone leading the upside.

Key takeaways

Net sales grew year-over-year, supported primarily by a strong performance in China and over $6 million in U.S. quarterly sales, a new company milestone.
Adjusted EBITDA turned positive for the first time in the quarter, reflecting improved operational discipline and margin expansion.
China normalized inventory levels and demonstrated sustained demand growth for both EVO and newly launched EVO+ ICL lenses.
FDA approval expanding EVO ICL indications in the U.S. broadens the addressable market, with early signs of increased surgeon adoption.
Geopolitical and trade disruptions impacted less than $2 million in net sales outside China and the U.S., with ongoing caution in certain regions.

View recap

SLR Senior Investment Corp.

SUNS Q1 2026

Reported: 2026-05-15

Sunrise Realty Trust shares rose 7.9% following earnings, driven by better-than-expected distributable earnings supported by capital recycling activities and the favorable resolution of a non-performing hotel asset.

Key takeaways

Generated distributable earnings of $0.35 per share, covering the $0.30 dividend.
Earnings benefited from a short-term loan on a Colorado property, new loan closings, and a loan payoff on a multifamily asset in Dallas.
Completed foreclosure on a 162-key Class A hotel in Texas; engaged multiple interested buyers with attractive offers, positioning the asset for timely resolution.
Expanded senior secured revolving facility to $165 million, adding $25 million from Customers Bank.
Maintained focus on transitional real estate loans in southern U.S. markets, emphasizing deal structuring and underwriting discipline amid continued capital markets volatility.

View recap

Teekay Corporation

TK Q1 2026

Reported: 2026-05-15

Teekay's stock remained roughly flat, rising 0.2% after reporting steady first-quarter results in line with expectations amid strong tanker rates and continued fleet rationalization. The market reaction suggests no clear surprise on either margin or guidance despite high spot rates and operational execution.

Key takeaways

Q1 GAAP net income was $154 million ($4.42/share), and adjusted net income was $128 million ($3.69/share), notably higher than the prior quarter and year-over-year.
Spot tanker rates averaged ~$61,000/day for midsized tankers in Q1, near record highs for the period, supporting approximately $143 million in free cash flow and a debt-free balance sheet with nearly $1 billion cash.
Fleet renewal efforts continue with five modern vessels acquired or committed at $332 million and four older vessels sold or agreed to sell for $211 million; gains on sales totaled ~$55 million, part recognized in Q1 and remainder expected in Q2.
Chartering activity capitalized on strong spot market: outchartered Suezmax at $80,000/day (10-12 months) and Aframax at $60,000/day (12 months).
Management projects improved Q2 performance with spot rates accelerating further, supported by the ongoing Middle East supply disruption and trade inefficiencies elongating voyage distances.

View recap

TMC the metals company Inc.

TMC Q1 2026

Reported: 2026-05-15

The modest 1.2% stock uptick suggests investors are cautiously digesting progress on production partnerships and regulatory milestones, without clear excitement from the company’s cautious regulatory timeline and capital-intensive execution phase.

Key takeaways

Signed a production agreement with Allseas to complete and operate the first commercial polymetallic nodule collection system, signaling progress toward commercial readiness.
Expecting final permit issuance from NOAA in Q1 2027, but the regulatory process remains lengthy with multiple public comment periods and no mandatory timeline.
Allseas will fund a significant portion of preproduction costs, repayable after production commences, partially mitigating upfront capital risk.
Offshore operations design includes continuous nodule collection, transfer logistics, and synchronized vessel movements, highlighting operational complexity.
No new guidance or financial metrics disclosed; forward-looking statements emphasize risks and uncertainties inherent in project execution and regulatory approvals.

View recap

Teekay Tankers Ltd.

TNK Q1 2026

Reported: 2026-05-15

Teekay Group’s shares declined modestly by 0.3% despite solid operational performance, as elevated spot tanker rates and asset sales offset caution around ongoing geopolitical risks and a complex operational environment.

Key takeaways

Reported GAAP net income was $154 million ($4.42/share), with adjusted net income of $128 million ($3.69/share), improving significantly year-over-year.
Average spot tanker rates in Q1 were near record highs, around $61,000 per day for midsized vessels, driving $143 million in free cash flow and increasing the cash balance to nearly $1 billion with zero debt.
Fleet renewal continues with acquisition commitments of $332 million for 5 modern vessels and sale agreements for 4 older vessels totaling $211 million, including gains on asset sales exceeding $50 million.
Spot rates are expected to further improve in Q2 with VLCC, Suezmax, and Aframax bookings securing rates up to $141,800 per day for VLCCs and approximately 57-71% coverage across fleets.
Ongoing geopolitical disruptions, especially the Strait of Hormuz closure and Middle East oil supply shocks, create operational complexities and increased voyage distances, underpinning spot rates but adding uncertainty to the outlook.

View recap

Tecnicas Reunidas, S.A.

TRE.MC Q1 2026

Reported: 2026-05-15

Shares fell 5.1% following the earnings release as investors reacted to cautious execution amid Middle East disruptions and a significant EUR 45 million provision, which weighed on EBIT and highlighted operational challenges.

Key takeaways

Revenue grew 21% year-on-year to EUR 1.6 billion, driven by solid commercial activity mainly in the Middle East.
Underlying EBIT increased 36% to EUR 76 million, but after booking a EUR 45 million provision related to operational disruptions, reported EBIT dropped to EUR 31 million.
Approximately two-thirds of the backlog remains in the Middle East, with four major projects (EUR 1.5 billion backlog) significantly impacted by safety concerns, logistics bottlenecks, and site disruptions.
The company estimates the conflict impact at EUR 40-50 million, assuming no escalation and reopening of the Strait of Hormuz by end of Q2.
Despite challenges, TR maintains a substantial commercial pipeline (~EUR 40 billion), expecting short-term awards between EUR 4 billion and EUR 8 billion on three major projects by mid-June.

View recap

TUI AG

TUI1.DE Q2 2026

Reported: 2026-05-15

TUI's stock edged up 1.0% post-earnings, reflecting a mixed reaction to ongoing operational challenges and partially offsetting progress. Investor concerns linger around the significant disruptions in Q2 from geopolitical events and natural disasters, which pressured near-term results and visibility.

Key takeaways

Q2 and H1 results showed progress in transformation and efficiency initiatives, but were materially affected by the Iran war and the Jamaican hurricane, resulting in a roughly EUR 40 million cost hit in Q2 alone.
The company confirmed previously revised guidance with a wide EUR 1.1–1.4 billion range, citing limited visibility due to ongoing geopolitical uncertainty and market volatility.
Operational improvements include the rollout of a commercial airline management model in Belgium and the Netherlands, expansion in Romania and Italy, and AI-driven process efficiencies across markets.
Hotel occupancy was stable relative to last year when excluding Jamaica, where closures suppressed performance significantly; rates in unaffected regions increased modestly.
Cruise operations suffered delayed ship deployments and repatriation costs, with a EUR 20 million impact expected through mid-May as the situation normalizes.

View recap

United States Antimony Corporation

UAMY Q3 2026

Reported: 2026-05-15

Shares fell 4.0% as investors reacted negatively to margin compression driven by rising costs, flat sales, and a cautious tone on near-term profitability despite operational progress.

Key takeaways

Q1 sales were essentially flat at $6.8 million versus $7 million year-over-year, with antimony sales down 2% and zeolite sales down 7%.
Gross profit declined by $1.3 million due to higher labor, factory, import, and freight costs, which management attributed to investments in future production capacity.
Net loss widened to $11.3 million, largely reflecting $4.8 million in noncash stock compensation and a $4.1 million unrealized loss on equity investments.
Inventory increased significantly by $9.5 million to $22 million, indicating buildup for expected ramp-up later in the year.
The company highlighted progress in securing mining permits and government grants but did not commit to near-term earnings improvement, underscoring ongoing operational risk ahead.

View recap

Vishay Precision Group, Inc.

VPG Q1 2026

Reported: 2026-05-15

Shares surged 49.5% post-earnings, driven by better-than-expected order growth and an optimistic outlook for sustained expansion in AI-related demand and backlog across all segments.

Key takeaways

Q1 revenue reached $84.4 million, an 18% year-over-year increase, supported by broad-based growth in all three segments.
Orders totaled $102.1 million, up 26% sequentially, with a consolidated book-to-bill ratio of 1.21, the strongest since 2022.
Sensors segment orders jumped 29% sequentially, led by precision resistor demand for semiconductor equipment and AI infrastructure.
Measurement Systems bookings increased 32% sequentially despite a 7% sequential revenue decline, buoyed by defense and aerospace projects.
Management raised 2026 organic growth targets to 8-10% CAGR and forecast gross margins near 46.5%, signaling confidence in ongoing margin expansion amid investments.

View recap

Zix Corporation

VUZI Q1 2026

Reported: 2026-05-15

Vuzix shares edged up modestly by 2.0% following its Q1 2026 earnings report, reflecting a mixed investor reaction amid ongoing execution on OEM and waveguide development programs but without a clear catalyst to drive a stronger move.

Key takeaways

The company highlighted progressing OEM shipments for its Ultralight Pro smart glasses, with initial orders starting to ship to Amazon in Q2.
Expansion continues in enterprise and defense segments, including multiple six- and seven-figure development and production orders from Tier 1 defense suppliers and Collins Aerospace.
Waveguide technology remains central to Vuzix’s long-term strategy, with strengthened collaboration with Quanta Computer to scale production for AI-enabled smart glasses ecosystems.
There were no indications of guidance raises, margin improvements, or acceleration in key financial metrics to push shares higher beyond the mid-single-digit range.
Investor caution persists as management focuses on multi-year development projects that still have considerable execution risk before translating to meaningful product revenues.

View recap

Wolverine World Wide, Inc.

WWW Q1 2026

Reported: 2026-05-15

Shares declined 1.2% as investors digested a deceleration in key metric growth rates despite solid revenue gains and margin expansion, suggesting caution about the sustainability of momentum.

Key takeaways

Revenue grew 11% reported and 7% constant currency, driven by high single-digit growth at Merrell and mid-teens increase at Saucony.
Adjusted diluted EPS rose over 30% to $0.25, reflecting improved profitability alongside ongoing investments.
Merrell’s revenue growth slowed to 9% from 14% year-over-year last quarter, indicating a deceleration in its core outdoor segment.
Saucony delivered 15% revenue growth across all regions and categories, supported by new product launches like the Endorphin Azura.
The company emphasized strategic initiatives in e-commerce modernization and AI adoption, aiming to improve agility and efficiency going forward.

View recap

zSpace, Inc.

ZSPC Q1 2026

Reported: 2026-05-15

zSpace’s stock surged 53.3% following Q1 results that showed signs of stabilization and early revenue improvement after a challenging 2025, driven by better software and services performance and new product launches that boosted investor confidence.

Key takeaways

Q1 2026 revenues totaled $5.3 million, down 22% year-over-year, reflecting ongoing headwinds but an 8% sequential revenue increase.
Software and services revenue decline of 15% outpaced hardware, raising the software and services contribution to 47% of total revenue, up from 43% a year ago.
New product introduction included the zStylus One and an updated zSpace Studio, enhancing the product roadmap with patented innovation and curriculum-aligned software enhancements.
Customer engagements showed improvement with expansions in Danbury Public Schools, Kansas WorkforceONE, and Colorado mobile learning labs despite budget pressures.
The Board initiated a formal strategic alternatives review, indicating management’s focus on unlocking shareholder value amid valuation concerns.

View recap

Earnings Recaps

Allianz SE

Allogene Therapeutics, Inc.

Applied Materials, Inc.

AmpliTech Group, Inc.

Avino Silver & Gold Mines Ltd.

authID Inc. Common Stock

Birkenstock Holding plc

BK Technologies Corporation

Brookfield Corporation Class A Limited Voting Shares

BitGo Holdings, Inc.

Crescent Capital BDC, Inc.

CorMedix Inc.

Cisco Systems, Inc.

Capital Southwest Corporation

CuriosityStream Inc.

Dare Bioscience, Inc.

Dragonfly Energy Holdings Corp. Common Stock (NV)

DLocal Limited Class A Common Shares

Doximity, Inc.

DarioHealth Corp.

Exchange Income Corporation

Enovix Corporation Common Stock

Evolution Petroleum Corporation

Evolv Technologies Holdings Inc. Class A Common Stock

Faraday Future Intelligent Electric Inc.

Simplify Macro Strategy ETF

Franco-Nevada Corporation

Fermi Inc. Common Stock

FitLife Brands, Inc.

Forward Industries, Inc.

Galiano Gold Inc.

two

Glass House Brands Inc.

Globant S.A.

Genmab A/S

GrainCorp Limited

Humacyte Inc. Common Stock

SeaStar Medical Holding Corporation Common Stock

InPost S.A.

Innoviz Technologies Ltd.

Invivyd Inc. Common Stock

Jack in the Box Inc.

KULR Technology Group, Inc.

Leslie's, Inc.

LogicMark Inc. Common Stock

AEye Inc. Class A Common Stock

Laird Superfood, Inc.

Lifeway Foods, Inc.

Moving iMage Technologies Inc. Common Stock

Milestone Scientific Inc.

Munchener Ruckversicherungs-Gesellschaft Aktiengesellschaft in Munchen

MicroVision, Inc.

Nebius Group N.V.

Nano Nuclear Energy Inc

Nu Holdings Ltd. Class A Ordinary Shares

Ondas Holdings Inc.

Optex Systems Holdings, Inc

Orezone Gold Corporation

Planet 13 Holdings Inc.

Parex Resources Inc.

Reed's, Inc.

Algorhythm Holdings Inc.

Snail, Inc. Class A Common Stock

SoftBank Corp.

STAAR Surgical Company

SLR Senior Investment Corp.

Teekay Corporation

TMC the metals company Inc.

Teekay Tankers Ltd.

Tecnicas Reunidas, S.A.

TUI AG

United States Antimony Corporation

Vishay Precision Group, Inc.

Zix Corporation

Wolverine World Wide, Inc.

zSpace, Inc.

Community

Trending This Week

Notifications